OR WAIT 15 SECS
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Melanie Sena is community editor of Pharmaceutical Technology.
GSK and Amicus Therapeutics revise Fabry agreement entered into in July 2012.
GlaxoSmithKline (GSK) and Amicus Therapeutics have revised their drug-development under which Amicus has obtained global rights to develop and commercialize the investigational pharmacological chaperone migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Under the terms of the revised agreement:
Source: GlaxoSmithKline